Altimmune's Upcoming Investor Conferences Participation
GAITHERSBURG, Md. — Altimmune, Inc. (NASDAQ: ALT), a key player in the biopharmaceutical industry focusing on clinical advancements, has exciting plans to participate in two major investor conferences shortly. With a mission to propel healthcare innovation, Altimmune is set to engage with investors, showcasing its strategic direction and innovative therapeutics designed to address pressing health issues.
Highlights of the Conferences
The first event, the Guggenheim Inaugural Healthcare Innovation Conference, is scheduled to be held in Boston. This event will feature a fireside chat on Monday, bringing together leaders and influencers in the healthcare sector. Attendees will get insights into Altimmune’s strategic vision and innovative solutions, highlighting how the company is positioned to tackle contemporary health challenges.
Guggenheim Inaugural Healthcare Innovation Conference
This significant healthcare event will occur on Monday. Altimmune’s management will participate in a key session at 11:30 a.m. Eastern Time, providing investors with an opportunity to understand the company's growth trajectory, ongoing projects, and how they fit into the broader healthcare landscape.
UBS Global Healthcare Conference Experience
Following the Guggenheim event, Altimmune will also take part in the prestigious UBS Global Healthcare Conference in Rancho Palos Verdes, California. This conference will allow for one-on-one meetings on Wednesday, where interested investors can discuss the latest developments in detail. Additionally, there will be a fireside chat at 9:30 a.m. Pacific Time, where company leaders will address questions and share insights about the company’s future.
Engagement through Webcasts
For those unable to attend in person, these sessions will be live-streamed, allowing a broader audience to engage with the content. By making these discussions accessible online, Altimmune highlights its commitment to transparency and open communication with stakeholders. Interested parties can catch the sessions through the Events section on the company's official website.
Understanding Altimmune and Its Innovations
Altimmune is at the forefront of biopharmaceutical research and development, concentrating on innovative peptide-based therapeutics. The company actively develops pemvidutide, a GLP-1/glucagon dual receptor agonist. This therapeutic avenue aims to address critical health issues such as obesity, among other conditions, reflecting its commitment to enhancing patient care and outcomes.
Commitment to Healthcare Solutions
With its dedicated research team and strategic initiatives, Altimmune endeavors to provide next-generation solutions that utilize advanced biopharmaceutical techniques. By engaging at these conferences, Altimmune not only elevates its visibility but also fosters valuable relationships that can lead to collaborative opportunities within the healthcare ecosystem.
Company Contacts for Further Information
To ensure investors and stakeholders have access to relevant updates and information, Altimmune has provided direct contact details for individuals responsible for investor relations:
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
Email: ir@altimmune.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Email: Danielle.cantey@inizioevoke.com
Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
Email: lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
Email: jweilman@burnsmc.com
Frequently Asked Questions
What is Altimmune focusing on at the conferences?
Altimmune will discuss its innovative therapeutics and engage with investors to share insights on its growth and direction.
Will the sessions be available online?
Yes, both conferences will be webcast for broader access to those who cannot attend in person.
What are the main topics Altimmune will cover?
The company will highlight its advancements in peptide-based therapeutics and the development of pemvidutide for treating obesity.
Who can I contact for more information?
For inquiries, you can reach the company's investor relations team directly via the provided contact details.
How is Altimmune innovating in healthcare?
Altimmune focuses on developing next-generation therapies that leverage advanced biopharmaceutical methods to improve patient care and health outcomes.
